Gilead Sciences, Inc. (GILD) Balance Sheet
As of 2026-06-30 (10-Q), Gilead Sciences, Inc. (GILD) reported total assets of $49.4B and shareholders' equity of $11.8B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $3.2B. Long-term debt: $23.8B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GILDGilead Sciences, Inc.Follow GILD — free
—
Price chart with a free account
- Market cap
- 193.5B
- P/E TTM
- —
- Dividend yield
- 2.1%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.27 | 0.91 | 9.88 | 1.80 | 2.11 | 10.03 | 12.85 | 8.23 | 7.59 | 17.94 | 11.63 | 6.00 | 5.34 | 5.41 | 6.09 | 9.99 | 7.56 | 3.18 | |
| Short-term investments | 0.38 | 1.19 | 0.02 | 0.06 | 0.02 | 0.10 | 1.76 | 3.67 | 17.92 | 12.15 | 12.72 | 1.41 | 1.18 | 0.97 | 1.18 | 0.00 | 0.07 | 0.00 | |
| Receivables | 1.39 | 1.62 | 1.95 | 1.75 | 2.18 | 4.64 | 5.85 | 4.51 | 3.85 | 3.33 | 3.58 | 4.89 | 4.49 | 4.78 | 4.66 | 4.42 | 4.91 | 5.06 | |
| Inventory | 1.05 | 1.20 | 1.39 | 1.74 | 1.70 | 1.39 | 1.96 | 1.59 | 0.80 | 0.81 | 0.92 | 1.68 | 1.62 | 1.51 | 1.79 | 1.71 | 1.77 | 1.95 | |
| Current assets | 4.81 | 5.71 | 13.92 | 6.16 | 7.00 | 17.71 | 24.76 | 19.59 | 31.82 | 35.84 | 30.30 | 16.00 | 14.77 | 14.44 | 16.09 | 19.17 | 18.34 | 13.95 | |
| Total assets | 9.70 | 11.59 | 17.30 | 21.24 | 22.58 | 34.66 | 51.72 | 56.98 | 70.28 | 63.68 | 61.63 | 68.41 | 67.95 | 63.17 | 62.13 | 59.00 | 59.02 | 49.36 | |
| Current liabilities | 1.87 | 2.46 | 2.51 | 4.24 | 6.41 | 5.76 | 9.89 | 9.22 | 11.64 | 10.61 | 9.76 | 11.40 | 11.61 | 11.24 | 11.28 | 12.00 | 11.81 | 11.02 | |
| Long-term debt | 1.16 | 3.48 | 7.61 | 7.05 | 3.94 | 11.92 | 21.07 | 26.35 | 30.80 | 24.57 | 22.09 | 28.65 | 25.18 | 22.96 | 23.19 | 24.90 | 22.13 | 23.83 | |
| Short-term debt | 0.01 | 0.65 | 0.00 | 1.17 | 2.70 | 0.48 | 0.98 | 0.00 | 2.75 | 2.75 | 2.50 | 2.76 | 1.52 | 2.27 | 1.80 | 1.82 | 2.81 | 2.41 | |
| Shareholders' equity | 6.37 | 5.86 | 6.74 | 9.30 | 11.37 | 15.43 | 18.53 | 18.89 | 20.44 | 21.39 | 22.53 | 18.20 | 21.07 | 21.24 | 22.83 | 19.33 | 22.70 | 11.83 |
USD billions · SEC XBRL
Gilead Sciences, Inc. — questions
- How much cash does Gilead Sciences, Inc. have?
- $3.2B in cash and cash equivalents as of 2026-06-30.
- How much debt does Gilead Sciences, Inc. have?
- $23.8B of long-term debt and $2.4B due within a year as of 2026-06-30.
- What are Gilead Sciences, Inc.'s total assets?
- $49.4B as of 2026-06-30.
- What is Gilead Sciences, Inc.'s shareholders' equity?
- $11.8B as of 2026-06-30.
Every figure on this page comes from Gilead Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.